Safety and efficacy of the addition of IMM-101 Heat-Killed Whole Cell Mycobacterium obuense to standard stereotactic radiotherapy in locally advanced pancreatic cancer patients (LAPC-2 trial)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

28 Mar 2024 Status changed from active, no longer recruiting to completed.
01 Jun 2023 Results assessing the safety, feasibility, and efficacy of stereotactic body radiotherapy with IMM-101 vaccination in patients with locally advanced pancreatic cancer, published in the Radiotherapy and Oncology.
25 Mar 2021 According to an Immodulon Therapeutics media release, this trial is nearing completion.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com